Infinity Pharmaceuticals Stock Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Infinity Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Infinity Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's forward indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:4 | Last Split Date 2006-09-13 |
1 | Check Point Software Technologies SWOT analysis cybersecurity stalwart faces growth challenges | 01/14/2025 |
2 | Infinity Garage Door Repair Offers 247 Emergency Service Smart Home Upgrades in Las Vegas | 01/22/2025 |
3 | Infinity Natural Resources, Inc. Announces Full Exercise and Closing of Over-allotment Option | 02/06/2025 |
4 | Casino Group Change in the ownership structure of Infinity Advertising | 02/14/2025 |
5 | OPEX Corporation annonce des amliorations importantes au systme de stockage et de rcupration automatis Infinity | 02/18/2025 |
6 | Samenvatting OPEX Corporation kondigt belangrijke verbeteringen aan het Infinity Automated Storage Retrieval System aan | 02/19/2025 |
7 | JBL Amplifies SXSW 2025 as Official Audio Partner, Unveiling Fan-Favorite Next-Generation Flip 7 and Charge 6 Amid a Groundbreaking Week of Music and Innovation | 02/20/2025 |
8 | Discover Infinity Logistics and Transport Ventures Plus 2 Other Promising Penny Stocks | 02/21/2025 |
9 | OPEX expose ses solutions dautomatisation dentrept de nouvelle gnration en Allemagne lors de LogiMAT, le plus grand salon europen de lentrept et de lintralogist... | 02/25/2025 |
| Begin Period Cash Flow | 80.9 M | |
| Total Cashflows From Investing Activities | -55 K |
Infinity |
Infinity Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Infinity Pharmaceuticals on November 28, 2024 and sell it today you would lose (0.01) from holding Infinity Pharmaceuticals or give up 100.0% of portfolio value over 90 days. Infinity Pharmaceuticals is currently producing negative expected returns and takes up 13.1306% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Infinity, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Infinity Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Infinity Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Infinity Pharmaceuticals, and traders can use it to determine the average amount a Infinity Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1313
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INFIQ |
Estimated Market Risk
| 13.13 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.72 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Infinity Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Infinity Pharmaceuticals by adding Infinity Pharmaceuticals to a well-diversified portfolio.
Infinity Pharmaceuticals Fundamentals Growth
Infinity Stock prices reflect investors' perceptions of the future prospects and financial health of Infinity Pharmaceuticals, and Infinity Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Infinity Stock performance.
| Return On Asset | -0.61 | ||||
| Operating Margin | (17.36) % | ||||
| Current Valuation | (17.11 M) | ||||
| Shares Outstanding | 90.76 M | ||||
| Price To Book | 8.03 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 2.59 M | ||||
| Gross Profit | (25.96 M) | ||||
| EBITDA | (43.73 M) | ||||
| Net Income | (44.37 M) | ||||
| Total Debt | 917 K | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (42.43 M) | ||||
| Earnings Per Share | (0.46) X | ||||
| Market Capitalization | 908 | ||||
| Total Asset | 42.15 M | ||||
| Retained Earnings | (855.95 M) | ||||
| Working Capital | 26.67 M | ||||
About Infinity Pharmaceuticals Performance
Assessing Infinity Pharmaceuticals' fundamental ratios provides investors with valuable insights into Infinity Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Infinity Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.95) | (0.99) | |
| Return On Capital Employed | (1.81) | (1.90) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | 2.10 | 2.20 |
Things to note about Infinity Pharmaceuticals performance evaluation
Checking the ongoing alerts about Infinity Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Infinity Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Infinity Pharmaceuticals generated a negative expected return over the last 90 days | |
| Infinity Pharmaceuticals has high historical volatility and very poor performance | |
| Infinity Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Infinity Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 2.59 M. Net Loss for the year was (44.37 M) with loss before overhead, payroll, taxes, and interest of (25.96 M). | |
| Infinity Pharmaceuticals generates negative cash flow from operations | |
| Latest headline from businesswire.com: OPEX expose ses solutions dautomatisation dentrept de nouvelle gnration en Allemagne lors de LogiMAT, le plus grand salon europen de lentrept et de lintralogistique |
- Analyzing Infinity Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Infinity Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Infinity Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Infinity Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Infinity Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Infinity Pharmaceuticals' stock. These opinions can provide insight into Infinity Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Infinity Stock Analysis
When running Infinity Pharmaceuticals' price analysis, check to measure Infinity Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuticals is operating at the current time. Most of Infinity Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infinity Pharmaceuticals' price. Additionally, you may evaluate how the addition of Infinity Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.